Type 1 Diabetes Mellitus Clinical Trial
Official title:
Efalizumab (Raptiva) Combined With Sirolimus in Type 1 Diabetic Islet Allograft Recipients
The primary objective of this protocol is to test the safety and efficacy of a treatment
regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed
by withdrawal of efalizumab and maintenance therapy with sirolimus, for the prevention of the
destruction and rejection of islet transplants in type 1 diabetic recipients.
Genentech, the manufacturer of efalizumab voluntarily withdrew the drug from the U.S. market
in April of 2009. Previously transplanted subjects have been transitioned to alternative
immunosuppressives and no new subjects will be transplanted under this protocol.
The purpose of this study is to improve the applicability of islet transplantation for
treatment of type 1 diabetes utilizing a novel immunosuppressive regimen centered on the use
of adhesion molecule blockade with an anti-LFA-1 antibody (efalizumab). The
lymphocyte-function associated antigen-1 (LFA-1) adhesion molecule is expressed on multiple
cellular populations including T cells, B cells, and NK cells and is important in
facilitating cell migration and homing. In addition, interaction of LFA-1 with its ligand
ICAM-1 on antigen presenting cells provides a powerful costimulatory signal for T cell
activation.
Animal models using anti-LFA-1 antibodies have shown impressive prolongation of vascularized
and cellular allograft survival. These potent immunosuppressive properties have also been
documented in several clinical trials with efalizumab, a humanized IgG1 monoclonal antibody
directed against LFA-1. The drug was found to be safe, well tolerated, and efficacious in
treating moderate to severe psoriasis.
More recently, a multicenter trial employing efalizumab in conjunction with prednisone,
sirolimus and cyclosporine maintenance immunosuppression in recipients of kidney allografts
showed an acceptable safety profile when used at a dose of 0.5mg/kg/week and excellent
rejection-free graft survival over the first 6 months after transplant.
This study represents the first clinical trial that applies adhesion molecule blockade with
efalizumab to prevent the immune response against pancreatic islets in the setting of type 1
diabetes mellitus, with the long-term goal of immunosuppression withdrawal.
Genentech, the manufacturer of efalizumab voluntarily withdrew the drug from the U.S. market
in April of 2009. Previously transplanted subjects have been transitioned to alternative
immunosuppressives and no new subjects will be transplanted under this protocol.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
| Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
| Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
| Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
| Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
| Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
| Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
| Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
| Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
| Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
| Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
| Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
| Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
| Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
| Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A | |
| Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Completed |
NCT02596204 -
Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring
|
N/A | |
| Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 |